ValiRx PLC said it has received acceptance from the Australian Patent Office for the patent application relating to its lead cancer compound, VAL 101, which is derived from the GeneICE technology platform for gene silencing.
Provided there is no opposition the full patent is anticipated to be issued in due course, the group said.
ValiRx holds the rights to GeneICE through its wholly owned subsidiary, ValiPharma Ltd, which has an exclusive worldwide license agreement with Imperial College Innovations Ltd.
GeneICE compounds have the potential to freeze the development and growth of cancerous cells and also have potential major applications in inflammatory disease and inherited genetic conditions.
Previous results have shown VAL 101's efficacy in several cell-based cancer models, including prostate, ovarian and pancreatic cancers in vitro.
No comments:
Post a Comment